Investor Presentaiton
Novo Nordisk Annual Report 2023
Introducing Novo Nordisk Strategic Aspirations
Risks
Management
Consolidated statements
Additional information
President and CEO, Lars
Fruergaard Jørgensen (left)
and Chair of the Board of
Directors, Helge Lund (right).
NOVO NORDISK
LETTER FROM THE CHAIR AND THE CEO
An extraordinary year of
innovation, growth and impact
It is a rare privilege for
any company to reach its
centenary; and even more
so to arrive at this milestone
in a position of strength.
As we reflect on 100 years
of driving change to defeat
serious chronic diseases, we
nevertheless acknowledge
that what got us here will
not be enough to take us
where we want to go.
The choices we make at this pivotal moment for our company are key to
shaping our long-term vision - one that extends beyond strengthening
leadership positions in our core therapy areas to becoming a driving
force for improving human health worldwide.
As our business continues to grow, so does our role in society. The
global burden of serious chronic diseases casts a long shadow, and
demands innovative, disruptive solutions that are as sustainable as they
are impactful. Our core contribution to this fight remains our industry-
leading therapeutic innovations, which benefited more than 40 million
people living with serious chronic diseases in 2023. Yet we are also
increasingly focused on prevention as we seek to understand and
address the root causes of the diseases we treat.
The unmet needs in type 2 diabetes and obesity are growing by the
day, and the rising prevalence of these closely related threats to global
health has created surging demand for our GLP-1-based therapies. This
has enabled us to reach more patients than at any point in our 100-year
history, contributing to strong sales growth across North America and
International Operations. However, it has also increased pressure on
our supply chain, resulting in periodic constraints across our portfolio
as we strive to keep pace with demand.
We have responded by investing heavily in expanding our production
capacity with the aim of serving millions more patients worldwide. In 2023
alone, we announced investments totalling more than DKK 75 billion
4View entire presentation